返回 Agenda
Session 8C: Policy Updates: Staying Informed and Understanding Their Potential Impact to the Medical Liaison Role
Session Chair(s)
Ed Cunningham, PharmD
, Sunovion Pharmaceuticals, Inc., United States
With the rapidly-changing political and health care landscape in the US, the environment manufacturers operate in is likely to increase in complexity. Medical Liaisons play a critical role in the exchange of scientific information with health care professionals, and the regulation of those communications remains in a state of flux. This session will provide an update on current legislative, judicial and regulatory developments, and their potential implications to the Medical Liaison role. A summary of the recent discussions related to the FDA’s hearing on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products, among other topics, will be discussed.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe and discuss current policies regulating medical liaison communications
- Explore recent updates and trends in order to better prepare and react to changes as they evolve
Speaker(s)
Torrey Cope, JD
Partner, Sidley Austin LLP, United States
Recent Developments Impacting the Ability to Communicate Truthful, Non-Misleading Information
Jamie Haney, JD
General Cousel - Lilly Diabetes Senior Director and Assistant General Counsel, Eli Lilly and Company, United States
Industry Perspective
Panel Discussion
, All Session Speakers, United States